Full-Time

Senior Clinical Scientist

Clinical Development

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS cancers

Biotechnology
Healthcare

Compensation Overview

$150k - $190kAnnually

Senior

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • BS/BA or master’s degree in a scientific discipline, or other relevant advanced degree in a health science field.
  • Minimum 4 years of experience in the pharmaceutical or biotechnology industry as a clinical scientist or related role.
  • Oncology experience is preferred.
  • Thrives in a collaborative team setting and is driven by a desire to deploy innovative approaches and technologies in a high-energy environment.
  • Detail-oriented with ability prioritize tasks and function independently as appropriate.
  • Strong organizational skills and an ability to interpret, discuss, and report trial/program level data effectively and identify trends.
  • Proficient with software tools (Microsoft Office), Electronic Data Capture, and other custom web-based software.
  • Excellent written and verbal communication skills.
Responsibilities
  • Contribute to clinical development strategy and execution of the Clinical Development Plan (CDP) with a focus on early-phase development.
  • Partner with cross-functional teams with oversight from senior team members to conduct clinical studies, including study start up, execution and close out activities, data review/analysis, and preparation of study reports.
  • Contribute to the development of program-level documents, including but not limited to clinical protocols, investigator’s brochure, clinical study reports, abstracts and manuscripts, presentations, and various other internal and external documents and communications as needed.
  • Conduct ongoing data reviews; prepare and present summaries to internal and external stakeholders.
  • Ensure trial implementation according to the protocol and analyze information to assess issues relating to protocol conduct and/or individual subject safety.
  • Interact with internal and external stakeholders (investigators, study sites, vendors, committees, etc.) in support of clinical trial objectives; responds to or triages questions for appropriate escalation.
  • Conduct literature reviews as needed.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, which target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to concentrate their research and development efforts in this niche area. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

12%

1 year growth

36%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for research and development.
  • Increased interest in targeted therapies boosts investment and partnership opportunities.
  • Shift towards personalized medicine aligns with their focus on genetic mutations.

What critics are saying

  • Integration challenges with EQRx could disrupt operations and delay timelines.
  • EQRx's pricing model may conflict with Revolution Medicines' market strategies.
  • $600M public stock offering may dilute existing shareholder value.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive licensing with the University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?